An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers

American Journal of Drug and Alcohol Abuse

Volumn 41, Issue 1, 2015, Pages 52-56

  Mcclure, Erin A ^a   Baker, Nathaniel L ^a   Gipson, Cassandra D ^a   Carpenter, Matthew J ^a   Roper, Amanda P ^a   Froeliger, Brett E ^a   Kalivas, Peter W ^a   Gray, Kevin M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

N acetylcysteine; Pharmacotherapy; Safety; Smoking cessation; Tolerability; Varenicline

Indexed keywords

ACETYLCYSTEINE; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ABSTINENCE; ADULT; AGED; ARTICLE; BACKACHE; BLOATING; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEARTBURN; HUMAN; INCREASED APPETITE; INFLUENZA; INSOMNIA; MALE; MEDICATION COMPLIANCE; MOOD DISORDER; NAUSEA; RESTLESSNESS; SELF REPORT; SMOKING; SMOKING CESSATION; STOMACH PAIN; TOBACCO DEPENDENCE; UPPER RESPIRATORY TRACT INFECTION; VIVID DREAM; VOMITING; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG THERAPY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PILOT STUDY; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BENZAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PILOT PROJECTS; QUINOXALINES; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; VARENICLINE;

EID: 84917695097     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2014.933839     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Quitting smoking among adults-United States, 2001-2010. MMWR 2011;60: 1513-1519.
2. Cohen S, Lichtenstein E, Prochaska JO, Rossi JS, Gritz ER, Carr CR, Orleans CT, et al. Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psycholog 1989;44:1355-1365.
3. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Internal Med 2003;18:1053-1057.
4. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, et al, Varenicline Phase 3 Study G. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. Sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006;296:47-55.
5. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, et al, Varenicline Phase 3 Study G. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006;296:56-63.
6. Oncken C, Gonzales D, Nides M, Rennard S,Watsky E, Billing CB, Anziano R, Reeves K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Internal Med 2006;166:1571-1577.
7. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316-325.
8. McClure EA, Vandrey RG, Johnson MW, Stitzer ML. Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine Tobacco Res 2013;15:139-148.
9. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, et al. Varenicline improves mood and cognition during smoking abstinence. Biolog Psychiat 2009;65: 144-149.
10. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008;197:371-377.
11. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Safety 2009;32:119-135.
12. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: An overview and network meta-Analysis. Cochrane Database Syst Rev 2013;5:CD009329.
13. Kalivas PW, Lalumiere RT, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology 2009;56:169-173.
14. Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Molec Psychiat 2011;16: 974-986.
15. Gipson CD, Reissner KJ, Kupchik YM, Smith AC, Stankeviciute N, Hensley-Simon ME, Kalivas PW. Reinstatement of nicotine seeking is mediated by glutamatergic plasticity. Proc Natl Acad Sci USA 2013;110:9124-9129.
16. LaLumiere RT, Kalivas PW. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci 2008; 28:3170-3177.
17. Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, Markou A, Kalivas PW. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biolog Psychiat 2009;65:841-845.
18. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, Kalivas PW. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009;12:182-189.
19. Ramirez-Nino AM, D'Souza MS, Markou A. N-Acetylcysteine decreased nicotine self-Administration and cue-induced reinstatement of nicotine seeking in rats: Comparison with the effects of Nacetylcysteine on food responding and food seeking. Psychopharmacology 2013;225:473-482.
20. Reichel CM, Moussawi K, Do PH, Kalivas PW, See RE. Chronic N-Acetylcysteine during abstinence or extinction after cocaine selfadministration produces enduring reductions in drug seeking. J Pharmacol Experim Therapeut 2011;337:487-493.
21. Zhou W, Kalivas PW. N-Acetylcysteine reduces extinction responding and induces enduring reductions in cue-And heroin-induced drug-seeking. Biol Psychiat 2008;63:338-340.
22. Moussawi K, Zhou W, Shen H, Reichel CM, See RE, Carr DB, Kalivas PW. Reversing cocaine-induced synaptic potentiation provides enduring protection from relapse. Proc Natl Acad Sci USA 2011;108:385-390.
23. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of Nacetylcysteine in neuropsychiatry. Trends Pharmacolog Sci 2013; 34:167-177.
24. McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-Acetylcysteine in the management of substance use disorders. CNS Drugs 2014;28:95-106.
25. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-Acetylcysteine in cannabisdependent adolescents. Am J Psychiat 2012;169:805-812.
26. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-Acetylcysteine in the treatment of nicotine dependence: A double-blind placebo-controlled pilot study. Eur Addict Res 2011;17:211-216.
27. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-Term N-Acetylcysteine in chronic bronchopulmonary disease: A meta-Analysis of published double-blind, placebocontrolled clinical trials. Clin Therapeut 2000;22:209-221.
28. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of Nacetylcysteine in the treatment of cocaine dependence. Am J Addict 2013;22:443-452.
29. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, et al. Safety and tolerability of Nacetylcysteine in cocaine-dependent individuals. Am J Addictions 2006;15:105-110.
30. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addiction 1991;86: 1119-1127.
31. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addiction 1988;83:393-402.
32. Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory II (BDI-II). San Antonio, TX: Psychology Corporation; 1996.
33. Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, Fisher P, Zelazny J, Burke A, Oquendo M, Mann J. Columbia-Suicide Severity Rating Scale (C-SSRS), 2007.
34. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tobacco Res 2001;3:7-16.
35. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiat 1986;43:289-294.
36. Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C, Rose JE. Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tobacco Res 2001;3:101-109.
37. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Informatics 2009;42: 377-381.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Ed.; Arlington, VA: American Psychiatric Publishing; 2013.
39. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tobacco Res 2002;4:149-159.